GLP-1 Agonists Compared: Semaglutide, Tirzepatide, and More
With multiple GLP-1 receptor agonists now available for weight loss and diabetes management, choosing the right medication can feel overwhelming. Each GLP-1 medication has a distinct pharmacological profile, dosing schedule, weight loss potential, side effect pattern, and cost structure. This comprehensive comparison breaks down every major GLP-1 receptor agonist on the market, including tirzepatide, semaglutide, liraglutide, dulaglutide, and exenatide, so you and your healthcare provider can make an informed decision about which option best fits your health goals, lifestyle, and budget.
For a foundational overview of how these medications work at the biological level, start with our guide on understanding GLP-1 medications.
Complete Medication Comparison
The following table provides a high-level comparison of all five major GLP-1 receptor agonists currently available. Each medication targets the GLP-1 receptor (and in tirzepatide's case, also the GIP receptor), but they differ meaningfully in dosing frequency, weight loss efficacy, available formulations, and cost.
| Medication | Type | Dosing | Weight Loss | Brand Names |
|---|---|---|---|---|
| Tirzepatide | GIP + GLP-1 | Weekly injection | 15-22% | Mounjaro, Zepbound |
| Semaglutide | GLP-1 only | Weekly injection | 12-15% | Ozempic, Wegovy |
| Liraglutide | GLP-1 only | Daily injection | 8-12% | Saxenda, Victoza |
| Dulaglutide | GLP-1 only | Weekly injection | 10-13% | Trulicity |
| Exenatide | GLP-1 only | Daily or weekly | 6-10% | Byetta, Bydureon |
Detailed Medication Profiles
Each GLP-1 medication has unique characteristics that make it better suited for certain patients and situations. The following profiles detail the mechanism, clinical evidence, advantages, limitations, and ideal patient profile for each option.
Tirzepatide (Mounjaro / Zepbound) - Most Effective for Weight Loss
- Mechanism: Dual GIP + GLP-1 receptor agonist. Tirzepatide is unique among GLP-1 medications because it activates two incretin receptors simultaneously, producing enhanced effects on appetite suppression, insulin sensitivity, and metabolic function
- Clinical evidence: The SURMOUNT clinical trial program demonstrated average weight loss of 20-22% of body weight at the highest dose (15mg), with some participants losing over 25%. These are the highest weight loss results of any GLP-1 medication to date
- Dosing schedule: Weekly subcutaneous injection, starting at 2.5mg and titrating upward through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum of 15mg based on tolerability and response
- Cost: Brand name $1,000-1,400 per month without insurance. Compounded versions typically $300-500 per month through telehealth platforms
- Pros: Highest weight loss results, weekly dosing convenience, substantial improvements in metabolic markers including A1C, blood pressure, and triglycerides, potentially superior insulin sensitization from the GIP component
- Cons: Higher cost than semaglutide, stronger initial gastrointestinal side effects during titration, less long-term safety data compared to older GLP-1 medications, availability can be limited
- Best for: Patients seeking maximum weight loss, those with higher BMI who need aggressive intervention, patients with significant insulin resistance or prediabetes, and those who didn't achieve adequate results with semaglutide alone
Semaglutide (Ozempic / Wegovy) - The Balanced Choice
- Mechanism: Selective GLP-1 receptor agonist with a long half-life engineered through albumin binding, allowing once-weekly dosing. Acts on appetite centers in the hypothalamus, slows gastric emptying, and enhances glucose-dependent insulin secretion
- Clinical evidence: The STEP clinical trial program showed average weight loss of 15-17% of body weight with the 2.4mg dose. The SELECT trial additionally demonstrated a 20% reduction in major cardiovascular events in overweight or obese adults
- Dosing schedule: Weekly subcutaneous injection, starting at 0.25mg and titrating through 0.5mg, 1.0mg, 1.7mg, to a maximum of 2.4mg for weight management
- Cost: Brand name $1,300-1,500 per month without insurance. Compounded versions typically $200-400 per month through telehealth platforms
- Pros: Excellent efficacy with robust clinical evidence, weekly dosing, most extensively studied GLP-1 for weight loss, proven cardiovascular benefits, widely available including compounded formulations, lower cost for compounded versions
- Cons: Gastrointestinal side effects during titration, requires gradual dose escalation over 4-5 months, some patients plateau at lower weight loss than tirzepatide
- Best for: Most patients starting GLP-1 therapy, those seeking a well-studied option with proven cardiovascular benefits, cost-conscious patients, and those with moderate weight loss goals (15-17% body weight)
For detailed guidance on getting started, see our how to start semaglutide guide.
Liraglutide (Saxenda / Victoza) - The Daily Option with Longest Track Record
- Mechanism: GLP-1 receptor agonist with approximately 97% amino acid sequence homology to native human GLP-1. Shorter half-life than semaglutide necessitates daily dosing
- Clinical evidence: The SCALE clinical trial program demonstrated average weight loss of 8-10% of body weight. Saxenda has the longest safety track record among GLP-1 medications approved for weight management, with FDA approval since 2014
- Dosing schedule: Daily subcutaneous injection, starting at 0.6mg and increasing weekly by 0.6mg to a target dose of 3.0mg
- Cost: Brand name $1,300-1,500 per month without insurance. May be covered by some insurance plans that don't cover newer options
- Pros: Longest safety track record for weight management, daily dosing allows more granular dose control, well-studied in diverse populations, established insurance coverage pathways
- Cons: Daily injection requirement (less convenient than weekly options), lower weight loss compared to semaglutide and tirzepatide, higher cost relative to efficacy, no compounded versions widely available
- Best for: Patients who prefer daily dosing for fine-tuned control, those whose insurance covers Saxenda but not newer options, patients wanting the medication with the longest weight management safety record
Dulaglutide (Trulicity) - The Established Weekly Option
- Mechanism: GLP-1 receptor agonist with a large molecular structure that extends its half-life to allow weekly dosing. Uses an easy-to-use pre-filled pen device
- Clinical evidence: The AWARD trial program and REWIND cardiovascular outcomes trial demonstrated moderate weight loss of 10-13% and significant cardiovascular benefits, including reduced major cardiovascular events in patients with and without established cardiovascular disease
- Dosing schedule: Weekly subcutaneous injection at doses of 0.75mg, 1.5mg, 3.0mg, or 4.5mg. Uses a single-dose, ready-to-use pen that hides the needle
- Cost: $900-1,100 per month without insurance. Often covered by diabetes-focused insurance plans
- Pros: Weekly dosing, user-friendly pen design with hidden needle (good for needle-averse patients), strong cardiovascular evidence from the REWIND trial, good tolerability profile
- Cons: Lower weight loss than semaglutide or tirzepatide, primarily approved for type 2 diabetes (not specifically for weight management), limited compounded availability
- Best for: Diabetic patients prioritizing cardiovascular outcomes, those who are needle-averse (hidden needle design), patients whose insurance covers Trulicity for diabetes management
Exenatide (Byetta / Bydureon) - The Original GLP-1
- Mechanism: Synthetic version of exendin-4, a compound originally isolated from Gila monster saliva. It was the first GLP-1 receptor agonist approved for clinical use
- Clinical evidence: Moderate weight loss of 6-10% of body weight in clinical trials. While less effective for weight loss than newer options, it has the longest overall safety record in the GLP-1 class
- Dosing schedule: Byetta requires twice-daily injections (5mcg or 10mcg). Bydureon BCise is a once-weekly extended-release formulation (2mg)
- Cost: $800-1,000 per month without insurance for the weekly formulation
- Pros: Longest overall safety record of any GLP-1 medication, weekly extended-release option available, well-understood pharmacology
- Cons: Lowest weight loss efficacy among current options, the daily formulation requires twice-daily injections, injection site nodules can occur with extended-release version, largely superseded by newer medications
- Best for: Patients with specific insurance coverage for exenatide, those who have tolerability issues with newer GLP-1 medications, diabetic patients in specialized treatment protocols
How to Choose the Right GLP-1 Medication
Selecting the optimal GLP-1 medication involves weighing multiple factors against your individual priorities. There is no single best medication for everyone, and the right choice depends on a combination of clinical factors, personal preferences, and practical considerations.
Key Decision Factors
- Weight loss goals: If you need maximum weight loss (20%+ of body weight), tirzepatide offers the strongest clinical evidence. For moderate goals (15-17%), semaglutide provides excellent results at a lower cost. If 8-12% body weight loss would meet your health objectives, liraglutide or dulaglutide may suffice
- Injection preference: Most patients strongly prefer weekly injections over daily. If weekly dosing is important to you, semaglutide, tirzepatide, dulaglutide, or extended-release exenatide are your options. Only liraglutide and immediate-release exenatide require daily injections
- Cost and insurance considerations: Compounded semaglutide ($200-400/month) is typically the most affordable option. Compounded tirzepatide runs $300-500/month. Brand-name costs vary widely based on insurance coverage. Some insurance plans cover certain GLP-1 medications only for diabetes, not weight loss
- Side effect sensitivity: If you have a sensitive stomach or are concerned about gastrointestinal side effects, starting with a lower-potency option and slower titration may be advisable. All GLP-1 medications cause similar gastrointestinal side effects, but the intensity can vary
- Cardiovascular history: Both semaglutide (SELECT trial) and dulaglutide (REWIND trial) have demonstrated cardiovascular benefits in clinical outcomes trials. If reducing cardiovascular risk is a priority alongside weight loss, these options deserve extra consideration
- Medical history: Certain conditions may favor one medication over another. Discuss your complete medical history with your provider to identify any factors that influence the choice. Our eligibility guide covers the key contraindications to consider
Side Effect Comparison Across All GLP-1 Medications
All GLP-1 receptor agonists share a similar core side effect profile because they act through the same receptor pathway. However, the frequency and severity of side effects can vary between medications and between individual patients. Understanding these patterns helps set appropriate expectations.
Common Side Effects Shared Across All GLP-1s
- Nausea: The most common side effect, affecting 20-45% of patients. Usually most pronounced during dose increases and typically resolves within 4-8 weeks at each dose level
- Diarrhea or constipation: Gastrointestinal motility changes affect 10-20% of patients. Constipation is more common with semaglutide; diarrhea may be slightly more common with tirzepatide
- Decreased appetite: This is the desired therapeutic effect but can feel concerning initially. Affects virtually all patients to some degree
- Fatigue: Common during titration, often related to caloric reduction rather than a direct drug effect. Typically improves as your body adjusts to the new caloric intake
- Injection site reactions: Mild redness, itching, or discomfort at the injection site occurs in 5-10% of patients. Usually resolves within 24 hours
- Headache: Reported by 10-15% of patients, particularly during the initial weeks. Often related to dehydration or caloric changes
For practical strategies to handle these side effects, visit our comprehensive guide on managing GLP-1 side effects. If side effects become severe, our guide on when to call your doctor helps you determine the appropriate response.
Rare but Serious Side Effects to Monitor
All GLP-1 medications share warnings for pancreatitis, gallbladder disease, and thyroid C-cell tumors (observed in animal studies). These serious side effects are rare but require awareness and appropriate monitoring. Regular lab monitoring helps detect early signs of complications before they become serious.
Cost Comparison and Value Analysis
Cost is often one of the most significant factors in medication selection. The landscape of GLP-1 pricing is complex, with brand-name, insurance, and compounded options creating very different cost experiences.
| Medication | Brand (No Insurance) | Brand (With Insurance) | Compounded |
|---|---|---|---|
| Tirzepatide | $1,000-1,400/mo | $25-150/mo | $300-500/mo |
| Semaglutide | $1,300-1,500/mo | $25-100/mo | $200-400/mo |
| Liraglutide | $1,300-1,500/mo | $25-100/mo | Limited availability |
| Dulaglutide | $900-1,100/mo | $25-75/mo | Not available |
| Exenatide ER | $800-1,000/mo | $25-75/mo | Not available |
When comparing costs, consider the total value proposition, not just the monthly price. A medication that costs more per month but produces significantly greater weight loss may represent better long-term value, especially when factoring in reduced costs from improvements in obesity-related conditions like diabetes, hypertension, and sleep apnea. For tips on navigating the purchasing process safely, see our guide on buying semaglutide online safely.
Switching Between GLP-1 Medications
Some patients may benefit from switching between GLP-1 medications during their treatment journey. Common reasons for switching include insufficient weight loss, intolerable side effects, cost changes, or insurance coverage shifts.
When switching from one GLP-1 to another, your provider will typically start you at a lower dose of the new medication and follow the standard titration schedule, even if you were on a high dose of the previous medication. This approach minimizes the risk of enhanced gastrointestinal side effects from switching. There is usually no washout period required between GLP-1 medications, though your provider will determine the optimal timing based on your specific situation.
The most common switch pathway today is from semaglutide to tirzepatide for patients seeking greater weight loss, or from tirzepatide to semaglutide for patients who want to reduce costs while maintaining results at a lower dose.
Frequently Asked Questions
Which GLP-1 medication causes the least nausea?
All GLP-1 medications can cause nausea, and it's difficult to predict individual responses. However, liraglutide's daily dosing allows more gradual dose adjustments, which some patients find causes less intense nausea. The newer weekly medications (semaglutide and tirzepatide) often cause more pronounced nausea during dose increases but have longer adjustment periods between increases.
Can I switch from semaglutide to tirzepatide if I plateau?
Yes, switching from semaglutide to tirzepatide is a common approach for patients who plateau or want greater weight loss. Your provider will typically start you at a lower dose of tirzepatide and titrate up. Many patients who switch report additional weight loss beyond what they achieved with semaglutide alone.
Is there an oral GLP-1 option?
Yes, oral semaglutide (Rybelsus) is available for type 2 diabetes at doses up to 14mg daily. A higher-dose oral semaglutide formulation (25mg and 50mg) is being studied for weight management, with promising clinical trial results. However, oral formulations currently require specific administration instructions (taken on an empty stomach with minimal water) and may have lower bioavailability than injections.
Are compounded GLP-1 medications as effective as brand-name versions?
Compounded semaglutide and tirzepatide contain the same active ingredient as their brand-name counterparts. When obtained from a properly licensed 503A or 503B compounding pharmacy with a valid prescription, they can be equally effective. The key is ensuring you obtain compounded medications from legitimate, licensed sources with verifiable quality testing.
How do GLP-1 medications compare to bariatric surgery?
Bariatric surgery typically produces greater average weight loss (25-35% of body weight) than any current GLP-1 medication. However, GLP-1 medications offer a non-surgical alternative with fewer risks, reversibility, and no recovery period. Many patients and providers view GLP-1 medications as an excellent option for those who don't qualify for or don't want surgery.
Do all GLP-1 medications require a prescription?
Yes, all GLP-1 receptor agonists are prescription medications that require evaluation and approval by a licensed healthcare provider. This is true for both brand-name and compounded versions. Any source selling GLP-1 medications without requiring a prescription is operating illegally and should be avoided.
What new GLP-1 medications are in the pipeline?
Several next-generation medications are in development, including triple-agonist compounds (targeting GLP-1, GIP, and glucagon receptors simultaneously) and oral formulations with improved bioavailability. These emerging therapies may offer even greater weight loss with fewer side effects, though they are still in clinical trials and not yet available for general use.
Related Resources
- Understanding GLP-1 Medications: Beginner's Guide
- How to Start Semaglutide
- Tirzepatide vs Semaglutide: Detailed Comparison
- Semaglutide Eligibility Requirements
- Managing GLP-1 Side Effects
- GLP-1 Lab Monitoring Guide
- Buying Semaglutide Online Safely
- When to Call Your Doctor on GLP-1s
- Semaglutide Dosage Guide
- Semaglutide vs Tirzepatide Key Differences
Sources
Scientific References
- Nauck MA, Quast DR, Wefers J, Meier JJ (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism.Read StudyDOI: 10.1016/j.molmet.2020.101102
- Jastreboff AM, Aronne LJ, Ahmad NN (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
- Pi-Sunyer X, Astrup A, Fujioka K (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1411892
- Wilding JPH, Batterham RL, Calanna S (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
- Gerstein HC, Colhoun HM, Dagenais GR (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). The Lancet.Read StudyDOI: 10.1016/S0140-6736(19)31149-3
Written by Trimi Medical Team
Our team of healthcare professionals specializes in weight management and metabolic health, providing comprehensive, evidence-based information about GLP-1 medications.
Medical Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to GLP-1 medications vary significantly. The weight loss percentages cited are averages from clinical trials, and individual results depend on many factors including starting weight, dose achieved, diet, exercise, and adherence. Consult with your healthcare provider to determine which GLP-1 medication is appropriate for your individual health needs, medical history, and goals.